adapt and survive: the changing face of r&d in the...
TRANSCRIPT
![Page 1: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/1.jpg)
Adapt and Survive: the Changing
Face of R&D in the Pharmaceutical
Industry and its Impact on
Cheminformatics
Dr. Wendy A. Warr
http://www.warr.com
Wendy Warr & Associates
![Page 2: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/2.jpg)
Wendy Warr & Associates
The Long Road to a New Medicine
Registration
Full development
Exploratory
development
Discovery
Source: Pfizer
![Page 3: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/3.jpg)
Drug Discovery and Development
Wendy Warr & Associates
![Page 4: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/4.jpg)
Wendy Warr & Associates
![Page 5: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/5.jpg)
Drug Discovery and Development
Wendy Warr & Associates
![Page 6: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/6.jpg)
Wendy Warr & Associates
From Concept to Product: 10-15
Years
Target identification and validation
Lead identification
Lead optimization
Preclinical development
Phase I
Phase II
Phase III
FDA review and scale up to manufacturing
Months/years
4-6 months
4-6 months
18 months
4-6 months
12-24 months
2-3 years
6-24 months
![Page 7: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/7.jpg)
Wendy Warr & Associates
Attrition
Stage Compounds In Compounds Out
Lead identification Up to 50,000 100-200
Lead optimization 100-200 20
Preclinical 20 1-5
Phase I 1-5 1-3
Phase II 1-3 1-2
Phase III 1-2 1
![Page 8: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/8.jpg)
The Cost
Wendy Warr & Associates
$-
$0.20
$0.40
$0.60
$0.80
$1.00
$1.20
$1.40
1975 1987 2000 2005
Billi
on
s (
Co
nsta
nt
do
llars
, ye
ar
2000)
Source: DiMasi, Grabowski. Managerial and
Decision Economics 2007, 28, 469-479
![Page 9: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/9.jpg)
Only Two in Ten Approved Drugs Produce
Revenues That Exceed Average R&D Costs
Wendy Warr & Associates
Source: Vernon, Golec, DiMasi. Health Economics Letters 2009
![Page 10: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/10.jpg)
Pharmaceutical Industry Productivity 2000-2010
Wendy Warr & Associates
![Page 11: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/11.jpg)
Number of New Molecular Entities
Approved
Wendy Warr & Associates
0
10
20
30
40
50
60 1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
![Page 12: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/12.jpg)
Wendy Warr & Associates
Why the Fall in Numbers of New
Chemical Entities?
• Easiest drugs already found
• Companies ultra-cautious about
withdrawals
• Disruption from mergers
• Or is it just the normal cycle?
![Page 13: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/13.jpg)
Number of New Molecular Entities
Approved
Wendy Warr & Associates
0
10
20
30
40
50
60 1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
![Page 14: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/14.jpg)
Investment in R&D
• R&D spending by drug companies in
the US fell by $1.2 billion in 2011
• US venture capital investment in biotech
fell by 43% in the first quarter of 2012
• National Institutes of Health budget will
not rise in 2013
Wendy Warr & Associates
![Page 15: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/15.jpg)
Wendy Warr & Associates
“One of the most frustrating things is
that people who bring you sugared
drinks and potato chips have a higher
multiple than an industry that will save
your life.”
Chris Viehbacher, CEO, Sanofi
![Page 16: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/16.jpg)
Measuring Return from
Investment in R&D
• 10/12 top pharma saw internal rate of
return (IRR) fall from 11.8% in 2010 to
8.4% in 2011
• Cost of bringing a drug to market
increased by 21%
• Number of compounds in late stage
development decreased from 23 to 18
Wendy Warr & Associates
Source: Deloitte and Thomson Reuters
![Page 17: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/17.jpg)
Measuring Return from
Investment in R&D
• More value from product commercialization
than lost from late-stage failures
• Non-R&D costs have declined; higher
operating margin
• To combat high costs in future, R&D
organizations will share capabilities in non-
competitive R&D areas
Wendy Warr & Associates
Source: Deloitte and Thomson Reuters
![Page 18: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/18.jpg)
Global Pharmaceutical Market
Wendy Warr & Associates
0
1
2
3
4
5
6
7
8
9
10
0
100
200
300
400
500
600
700
800
900
1000
Sales*
% Growth over previous year
*Constant $ in billions based on Q410
![Page 19: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/19.jpg)
Wendy Warr & Associates
Threats to the Industry
• CAGR in sales falling
• Generic competition (“the
patent cliff”)
• Price pressures
• Crowded markets
• Increasing R&D budgets
• Declining productivity
![Page 20: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/20.jpg)
Wendy Warr & Associates
The Solution?
• Mergers and acquisitions
• Cost cutting
• Restructuring
• Diversification
• In-licensing
• Alliances and outsourcing
• Target emerging markets
• Personalized medicine
• Portfolio management techniques
• Life cycle management
![Page 21: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/21.jpg)
Consolidation: Pharma
Pfizer now comprises the following companies:
• Warner Lambert (Agouron, Farmitalia,
Jouvenal, Parke-Davis)
• Pharmacia (Monsanto, Searle, Sugen,
Upjohn)
• Wyeth (American Cyanamid, American Home
Products, A.H.Robins, Genetic Institute)
Wendy Warr & Associates
Source: Bill Town
![Page 22: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/22.jpg)
Consolidation: Cheminformatics
Wendy Warr & Associates
Source: Bill Town
Acclerys now comprises the following former
companies:
MSI (Biodesign, Cambridge Molecular Design,
Polygen, Biosym, BioCad), Synopsys,
Oxford Molecular (Biostructure, CAChe,
Chemical Design, HDI, PSI (Fein Marquart),
GCG, Intelligenetics, Cambridge Combinatorial),
Synomics, SciTegic, Symyx (MDL (ORAC, OHS)),
Contur Software AB
![Page 23: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/23.jpg)
Wendy Warr & Associates
M&As: the Impact on Productivity
• Rationalization needed after merger
– TAs, research sites, conflicting informatics
• Disruption
• Momentum lost in research
• Entrenched camps develop
• Decision making loses objectivity
• Growth is largely from cost savings
• Benefits of scale not proven beyond a certain size
• M&As are self-limiting
![Page 24: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/24.jpg)
Product Lifecycle Management
• New indications
• Reformulations
• Combination drugs
• Rx to OTC
• Branded generics
• Mergers and acquisitions
• Alliances
• Pricing
• Patent protection
strategies
• New markets
• Refocusing R&D spend
• Reducing development
time
• Branding and rebranding
Wendy Warr & Associates
![Page 25: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/25.jpg)
Wendy Warr & Associates
Making R& D More Virtual
• Semantic technologies
• Computer-aided molecule design
• Predictive biosimulation – virtual cells, organs, animals
– complete digital model of man
Source: Steve Arlington, Pricewaterhouse Coopers
![Page 26: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/26.jpg)
RSC Prospect
Wendy Warr & Associates
![Page 27: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/27.jpg)
A Challenge for OCR
Wendy Warr & Associates
1870 1830 1910 1930
1969
Source: InfoChem
![Page 28: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/28.jpg)
“Article of the Future”
Wendy Warr & Associates
![Page 29: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/29.jpg)
Wendy Warr & Associates
Making R& D More Virtual
• Semantic technologies
• Computer-aided molecule design
• Predictive biosimulation – virtual cells, organs, animals
– complete digital model of man
Source: Steve Arlington, Pricewaterhouse Coopers
![Page 30: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/30.jpg)
Wendy Warr & Associates
Rational Drug Design
• Receptor structure unknown, ligand
structures unknown
• Receptor known, ligand known
• Receptor known, ligand unknown
• Receptor unknown, ligands known
![Page 31: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/31.jpg)
Wendy Warr & Associates
Rational Drug Design
• Receptor structure unknown, ligand
structures unknown
• Receptor known, ligand known
• Receptor known, ligand unknown
• Receptor unknown, ligands known
![Page 32: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/32.jpg)
Wendy Warr & Associates
Rational Drug Design
• Receptor structure unknown, ligand
structures unknown
• Receptor known, ligand known
• Receptor known, ligand unknown
• Receptor unknown, ligands known
![Page 33: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/33.jpg)
Wendy Warr & Associates
Docking a Ligand in a Protein
Source: Cambridge Crystallographic Data Centre
![Page 34: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/34.jpg)
Wendy Warr & Associates
Rational Drug Design
• Receptor structure unknown, ligand
structures unknown
• Receptor known, ligand known
• Receptor known, ligand unknown
• Receptor unknown, ligands known
![Page 35: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/35.jpg)
De novo Drug Design
Wendy Warr & Associates
Source: SimBioSys
![Page 36: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/36.jpg)
Wendy Warr & Associates
Rational Drug Design
• Receptor structure unknown, ligand
structures unknown
• Receptor known, ligand known
• Receptor known, ligand unknown
• Receptor unknown, ligands known
![Page 37: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/37.jpg)
Pharmacophore Model
Wendy Warr & Associates
Source: Accelrys
![Page 38: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/38.jpg)
Wendy Warr & Associates
Biological Activity
Structural Properties
+ Statistical
Relationship QSAR
Validation
toxicology pharmacology
calculated
properties
measured
properties
Physicochemical &
Quantitative Structure Activity
Relationships (QSAR)
![Page 39: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/39.jpg)
A Markush Structure
Wendy Warr & Associates
Frequency variation
n = 1-3
Substituent variation
Homology variation
Position variation( )n
methyl or ethyl
alkyl
amino
Frequency variation
n = 1-3
Substituent variation
Homology variation
Position variation( )n
methyl or ethyl
alkyl
amino
Source: Digital Chemistry
![Page 40: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/40.jpg)
Source:
ChemAxon
![Page 41: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/41.jpg)
Wendy Warr & Associates
Drug Discovery in the 1970s
![Page 42: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/42.jpg)
Wendy Warr & Associates
Drug Discovery in the 1970s
• Unplanned innovation
• Serendipity
• Drugs based on natural products
• Chemists used intuition
• Random screening
• Linear workflow
• Informatics only peripheral
![Page 43: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/43.jpg)
Wendy Warr & Associates
Advances of the 1990s
• The human genome project
• Genomics
• Proteomics
• Growth in knowledge of protein structures – X-ray crystallography
– NMR
– homology modeling
• High throughput screening (HTS)
• Combinatorial chemistry
• Bioinformatics and cheminformatics
![Page 44: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/44.jpg)
Wendy Warr & Associates
Drug Discovery Today
• Start with knowledge of a biological target
– and maybe a known protein structure
• Screen the fewest compounds needed
• Vast quantities of data
• Informatics is of strategic importance
• Informatics supports decision making
• Multi-disciplinary teams share knowledge
• “Fail early”: predict druglikeness
![Page 45: Adapt and Survive: the Changing Face of R&D in the ...infochim.u-strasbg.fr/CS3_2012/Lectures/Warr.pdf · •Cost of bringing a drug to market increased by 21% •Number of compounds](https://reader033.vdocument.in/reader033/viewer/2022050507/5f9899b874346352e27a0df0/html5/thumbnails/45.jpg)
Changing strategies
• Pharma 1.0 – Blockbuster model
– Focus on top line
• Pharma 2.0 – Strategies addressed in this talk
– Focus on bottom line
• Pharma 3.0 – Delivering health outcomes
– Being customer-centric
– Being payer-insightful
Wendy Warr & Associates
Source: Carolyn Buck Luce, Ernst &Young